Clostridium difficile bacteria, computer illustration. C. difficile is a normal inhabitant of the human intestine, but it can become a pathogen when antibiotics disrupt the normal intestinal flora and ...

Recurrent C. diff infection is when you contract a C. diff infection 2 to 8 weeks after completing treatment for a previous one. C. diff relapse is a recurrence of the same strain, while reinfection ...

Affecting roughly half a million Americans each year, bacterial infections caused by Clostridioides difficile—commonly known ...

Five insights from the report, written by Clayton Dalton, MD, a resident physician at Boston-based Massachusetts General Hospital: 1. In addition to antibiotic use being a risk factor for C. diff, ...

A newly developed antibiotic called EVG7 could offer a powerful new way to stop Clostridioides difficile, a dangerous gut bacterium that often returns after treatment. In mouse studies, researchers ...

C. diff colitis is inflammation of a person’s colon due to contagious bacteria. Most people with C. diff colitis fully recover, but in rare cases the condition can be life threatening. It is possible ...

FMT restores gut microbiota balance by transferring stool from healthy donors, mainly for recurrent C. difficile infections. Recent data shows FMT's high efficacy in preventing recurrent C. difficile, ...

Cases of Clostridioides difficile (C diff) have increasingly been reported outside of typical settings, and a survey of general practitioners in France found that many cases can be managed without ...

C. diff infection can cause diarrhea. While it may lead your poop to change color, there are no specific colors that are definitive evidence of having C. diff. According to the Centers for Disease ...

Please provide your email address to receive an email when new articles are posted on . Exposure to a contaminated nearly doubles a patient’s risk for hospital-onset C. difficile infection. This ...

Crestone, Inc. ("Crestone") today announced recent publication in the leading infectious disease journal, The Lancet Infectious Diseases, of positive results from a Phase 2 clinical trial evaluating ...

Acurx Pharmaceuticals (NASDAQ:ACXP) reported fourth-quarter and full-year 2025 results highlighting a stronger cash position ...